Munich - Delayed Quote EUR

Esperion Therapeutics Inc (0ET.MU)

2.1410

0.0000

(0.00%)

As of 8:05:03 AM GMT+1. Market Open.

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: P

GlobeNewswire 21 hours ago

ESPR
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website

GlobeNewswire 7 days ago

ESPR
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty – ANN ARBOR, Mich., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has closed on a series of financing transactions that will support the Company’s

GlobeNewswire 22 days ago

ESPR
Esperion Announces $210 Million Convertible Debt Financing

ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of (

GlobeNewswire 27 days ago

ESPR
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (

GlobeNewswire 28 days ago

ESPR
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.

Zacks last month

ESPR
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. "These submissions mark another pivotal milestone towards bringing our potentially lifesaving medications to the millions of patients around the world who need it,” said Sheldon Koenig,

GlobeNewswire last month

ESPR
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia. Bempedoic acid has a novel mechanism of action that inhibits a cholesterol synthesis pathway by acting on ATP (adenosine triphospha

GlobeNewswire last month

ESPR
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for appr

GlobeNewswire last month

ESPR
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation

GlobeNewswire last month

ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement

GlobeNewswire 2 months ago

ESPR
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion Therapeutics Inc (ESPR) reports significant revenue growth and strategic advancements, despite facing competitive and operational challenges.

GuruFocus.com 2 months ago

ESPR
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.

Zacks 2 months ago

ESPR
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -7.14% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ESPR
Esperion Therapeutics: Q3 Earnings Snapshot

ANN ARBOR, Mich. AP) — Esperion Therapeutics Inc. ESPR) on Thursday reported a loss of $29.5 million in its third quarter.

Associated Press Finance 2 months ago

ESPR
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWI

GlobeNewswire 2 months ago

ESPR
Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately

GlobeNewswire 2 months ago

ESPR
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

ESPR

JAZZ
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024. Featured ScienceBempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes TrialFeatured Science: Vascular Outcomes in the SpotlightNove

GlobeNewswire 2 months ago

ESPR
Esperion to Report Third Quarter 2024 Financial Results on November 7

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor a

GlobeNewswire 2 months ago

ESPR

Performance Overview

Return	0ET.MU	S&P 500
YTD	-2.95%	+0.19%
1-Year	-13.67%	+24.42%
3-Year	-46.42%	+26.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Esperion Therapeutics Inc (0ET.MU)

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Esperion Announces $210 Million Convertible Debt Financing

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7

Performance Overview